This is a multi-part message in MIME format.
------=_NextPart_000_0004_01BD3E19.52C6B2A0
Content-Type: text/plain;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
tasmar (Tolcapne)
Tasmar was realest in Australia a few =
weeks ago just for trial =20
Peripheral COMT inhibition is the next logical step towards inceasing =
the bioavailability of levodopa
it increases the bioavailability of orally taken levodopa with out =
affecting peak plasma concentrations
best for fluctuating P D
some P D reduce levodopa to avoid an increase dopaminergic side afect
side affect is some times diarrhea is caused after 4 weeks
interactions are minimal
------=_NextPart_000_0004_01BD3E19.52C6B2A0
Content-Type: text/html;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
<!DOCTYPE HTML PUBLIC "-//W3C//DTD W3 HTML//EN">
<HTML>
<HEAD>
<META content=3Dtext/html;charset=3Diso-8859-1 =
http-equiv=3DContent-Type>
<META content=3D'"MSHTML 4.71.1712.3"' name=3DGENERATOR>
</HEAD>
<BODY bgColor=3D#fffff0>
<DIV><STRONG><FONT color=3D#000000></FONT></STRONG> </DIV>
<DIV><FONT color=3D#000000><FONT color=3D#000000 size=3D2>tasmar=20
</FONT><STRONG>(Tolcapne)</STRONG></FONT></DIV>
<DIV><STRONG><FONT=20
color=3D#000000> &nb=
sp; &nbs=
p;  =
;=20
Tasmar was realest in Australia a few weeks ago just for trial =20
</FONT></STRONG></DIV>
<DIV><FONT size=3D2>Peripheral COMT inhibition is the next logical step =
towards=20
inceasing the bioavailability of levodopa</FONT></DIV>
<DIV><FONT size=3D2>it increases the bioavailability of orally taken =
levodopa with=20
out affecting peak plasma concentrations</FONT></DIV>
<DIV><FONT size=3D2>best for fluctuating P D</FONT></DIV>
<DIV><FONT size=3D2>some P D reduce levodopa to avoid an increase =
dopaminergic=20
side afect</FONT></DIV>
<DIV><FONT size=3D2>side affect is some times diarrhea is caused after 4 =
weeks</FONT></DIV>
<DIV><FONT size=3D2>interactions are minimal</FONT></DIV></BODY></HTML>
------=_NextPart_000_0004_01BD3E19.52C6B2A0--
